Abstract
A common feature of cancer cells is their ability to evade apoptosis as a result of alterations that block cell death signaling pathways. The extensive research efforts that elucidated these signaling pathways over the past decade have set the stage for the development of therapeutic agents that either kill cancer cells selectively or reset their apoptotic threshold. Over the past two years a number of these agents have been evaluated in preclinical and clinical trials. The results of these studies suggest that it might soon be possible to modulate apoptosis in cancer cells for therapeutic benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 668-676 |
Number of pages | 9 |
Journal | Current Opinion in Cell Biology |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2006 |
ASJC Scopus subject areas
- Cell Biology